Faster onset of action with topical levocabastine than with oral cetirizine

This international multicentre, open-label, parallel-group trial was undertaken to compare the therapeutic efficacy and tolerability of topical levocabastine and oral cetirizine in patients with perennial allergic rhinoconjunctivitis, with particular reference to the comparative onset of action of t...

Full description

Saved in:
Bibliographic Details
Main Authors: Michel A. Drouin, William H. Yang, Frederick Horak
Format: Article
Language:English
Published: Wiley 1995-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/S0962935195000779
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832549838900690944
author Michel A. Drouin
William H. Yang
Frederick Horak
author_facet Michel A. Drouin
William H. Yang
Frederick Horak
author_sort Michel A. Drouin
collection DOAJ
description This international multicentre, open-label, parallel-group trial was undertaken to compare the therapeutic efficacy and tolerability of topical levocabastine and oral cetirizine in patients with perennial allergic rhinoconjunctivitis, with particular reference to the comparative onset of action of the two drugs. A total of 207 patients were randomized to receive either levocabastine nasal spray (0.5 mg/ml, two sprays in each nostril twice daily) plus levocabastine eye drops as required (0.5 mg/ml, one drop in each eye twice daily p.r.n.) or cetirizine orally (10 mg once daily) with a treatment duration of 2 weeks. Onset of action was found to be significantly more rapid with levocabastine than with cetirizine for both nasal and ocular symptoms (p < 0.001). Within 15 min of study drug administration, 36% of levocabastine-treated patients reported relief from nasal symptoms and 32% relief from ocular symptoms compared with 10% and 17% of patients on cetirizine, respectively. At 1 h, the percentages of patients reporting relief were 76% and 38% for nasal symptoms, and 81% and 48% for ocular symptoms in the levocabastine and cetirizine treatment groups, respectively. At 8 h there were no differences between the two treatments. Overall therapeutic efficacy was found to be comparable in the two treatment groups over the 2-week study period with no significant intergroup differences in symptom severity or global therapeutic efficacy. Both drugs were well tolerated with no significant differences in the incidence or type of adverse reactions between the two groups. In conclusion, levocabastine eye drops and nasal spray are as effective and well tolerated as oral cetirizine for the treatment of perennial allergic rhinoconjunctivitis with the advantage of a significantly faster onset of action for both nasal and ocular symptoms.
format Article
id doaj-art-112f1019e17941c3989869b2adf53f92
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 1995-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-112f1019e17941c3989869b2adf53f922025-02-03T06:08:22ZengWileyMediators of Inflammation0962-93511466-18611995-01-0147S5S1010.1155/S0962935195000779Faster onset of action with topical levocabastine than with oral cetirizineMichel A. Drouin0William H. Yang1Frederick Horak2Section of Allergy and Clinical Immunology, Department of Medicine, Ottawa Civic Hospital, University of Ottawa, Ottawa, CanadaSection of Allergy and Clinical Immunology, Department of Medicine, Ottawa Civic Hospital, University of Ottawa, Ottawa, CanadaENT Clinic, University of Vienna, Vienna, AustriaThis international multicentre, open-label, parallel-group trial was undertaken to compare the therapeutic efficacy and tolerability of topical levocabastine and oral cetirizine in patients with perennial allergic rhinoconjunctivitis, with particular reference to the comparative onset of action of the two drugs. A total of 207 patients were randomized to receive either levocabastine nasal spray (0.5 mg/ml, two sprays in each nostril twice daily) plus levocabastine eye drops as required (0.5 mg/ml, one drop in each eye twice daily p.r.n.) or cetirizine orally (10 mg once daily) with a treatment duration of 2 weeks. Onset of action was found to be significantly more rapid with levocabastine than with cetirizine for both nasal and ocular symptoms (p < 0.001). Within 15 min of study drug administration, 36% of levocabastine-treated patients reported relief from nasal symptoms and 32% relief from ocular symptoms compared with 10% and 17% of patients on cetirizine, respectively. At 1 h, the percentages of patients reporting relief were 76% and 38% for nasal symptoms, and 81% and 48% for ocular symptoms in the levocabastine and cetirizine treatment groups, respectively. At 8 h there were no differences between the two treatments. Overall therapeutic efficacy was found to be comparable in the two treatment groups over the 2-week study period with no significant intergroup differences in symptom severity or global therapeutic efficacy. Both drugs were well tolerated with no significant differences in the incidence or type of adverse reactions between the two groups. In conclusion, levocabastine eye drops and nasal spray are as effective and well tolerated as oral cetirizine for the treatment of perennial allergic rhinoconjunctivitis with the advantage of a significantly faster onset of action for both nasal and ocular symptoms.http://dx.doi.org/10.1155/S0962935195000779
spellingShingle Michel A. Drouin
William H. Yang
Frederick Horak
Faster onset of action with topical levocabastine than with oral cetirizine
Mediators of Inflammation
title Faster onset of action with topical levocabastine than with oral cetirizine
title_full Faster onset of action with topical levocabastine than with oral cetirizine
title_fullStr Faster onset of action with topical levocabastine than with oral cetirizine
title_full_unstemmed Faster onset of action with topical levocabastine than with oral cetirizine
title_short Faster onset of action with topical levocabastine than with oral cetirizine
title_sort faster onset of action with topical levocabastine than with oral cetirizine
url http://dx.doi.org/10.1155/S0962935195000779
work_keys_str_mv AT micheladrouin fasteronsetofactionwithtopicallevocabastinethanwithoralcetirizine
AT williamhyang fasteronsetofactionwithtopicallevocabastinethanwithoralcetirizine
AT frederickhorak fasteronsetofactionwithtopicallevocabastinethanwithoralcetirizine